Inflammation and ovarian cancer

Macciò, Antonio; Madeddu, Clelia

doi:10.1016/j.cyto.2012.01.015

Cited by 250 publications

(178 citation statements)

References 82 publications

Supporting

Mentioning

175

Contrasting

Unclassified

Order By: Relevance

“…The surface epithelium of the ovary is a natural extension of the peritoneal lining and is directly exposed to any metabolic and environmental stress present in the peritoneal cavity (Maccio & Madeddu 2012). Regular cycling and release of ova from the ovary causes the ovarian epithelium to undergo regular cycles of wounding and repair throughout a female's reproductive life.…”

Section: The Role Of CXC Chemokines In Normal Ovarian Physiologymentioning

confidence: 99%

“…2; Mukaida & Baba 2012). At a molecular level, there is evidence that pro-inflammatory cytokines such as IL1, IL6 and TNF-a are linked to a poor prognosis in EOC patients (Clendenen et al 2011, Maccio & Madeddu 2012. Oxidative stress, cell necrosis and rapid cell division are hallmarks of chronic inflammation (Ness & Modugno 2006).…”

Section: Inflammation and The Ovarian Surface Epitheliummentioning

confidence: 99%

“…CXC chemokines in epithelial ovarian cancer Ness et al 2000, Fleming et al 2006, Son et al 2007, Coffelt & Scandurro 2008, Maccio & Madeddu 2012. As key mediators of inflammation, chemokines play two major roles: i) they are responsible for the recruitment and activation of immune cells into sites of malignancy (and possibly areas of pre-neoplastic growth) and ii) they mediate pro-and anti-angiogenic effects, processes required for the vascularisation and progression of tumours.…”

Section: Inflammation and The Ovarian Surface Epitheliummentioning

confidence: 99%

See 2 more Smart Citations

The emerging role of CXC chemokines in epithelial ovarian cancer

et al. 2012

View full text Add to dashboard Cite

In recent years, chemokines have generated intense investigations due to their involvement in both physiological and pathological processes of inflammation, particularly in ovarian biology. The physiological process of ovulation in the normal ovary involves various chemokines that mediate the healing of the ruptured endometrium. It is now being reported that many of these chemokines are also associated with the cancer of the ovary. Chronic inflammation underlies the progression of ovarian cancer; therefore, it raises the possibility that chemokines are involved in the inflammatory process and mediate immune responses that may favour or inhibit tumour progression. Ovarian cancer is a gynaecological cancer responsible for highest rate of mortality in women. Although there have been several investigations and advances in surgery and chemotherapy, the survival rate for this disease remains low. This is mainly because of a lack of specific symptoms and biomarkers for detection. In this review, we have discussed the emerging role of the CXC chemokines in epithelial ovarian cancer (EOC). The CXC group of chemokines is gaining importance in the field of ovarian cancer for being angiostatic and angiogenic in function. While there have been several studies on the angiogenesis function, emerging research shows that ELR K CXC chemokines, CXCL9 and CXCL10, are angiostatic. Importantly, the angiostatic chemokines can inhibit the progression of EOC. Given that there are currently no biomarkers or specific therapeutic targets for the disease, these chemokines are emerging as promising targets for therapy.

show abstract

Section: The Role Of CXC Chemokines In Normal Ovarian Physiologymentioning

confidence: 99%

Section: Inflammation and The Ovarian Surface Epitheliummentioning

confidence: 99%

Section: Inflammation and The Ovarian Surface Epitheliummentioning

confidence: 99%

See 1 more Smart Citation

The emerging role of CXC chemokines in epithelial ovarian cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Recent convincing data support the involvement of the inflammatory stromal microenvironment, caused by overexpression of cytokines or chemokines, in promoting ovarian tumorigenesis, cancer progression and resistance to chemotherapies (10). Among the cytokines reported to date, interleukin-6 (IL-6) is one of the pivotal immunoregulatory cytokines present in the ovarian cancer microenvironment; it induces several pathways leading to tumor proliferation, angiogenesis and chemoresistance (11).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-106a regulates phosphatase and tensin homologue expression and promotes the proliferation and invasion of ovarian cancer cells

et al. 2016

View full text Add to dashboard Cite

Abstract. Ovarian cancer is a leading cause of malignant gynecological tumor-related mortality among women. The treatment of ovarian cancer patients continues to be challenging. MicroRNA-106a (miR-106a) is widely expressed in diverse human tumors. In the present study, we investigated the biological and pathological roles of miR-106a in ovarian cancers. We found that miR-106a expression was significantly increased in primary ovarian cancer tissues and ovarian cancer cells compared with the level in normal tissues. Ectopic expression of an miR-106a inhibitor attenuated ovarian cancer cell proliferation and invasion. miR-106a promoted the growth and invasion of SKOV3 cells by targeting phosphatase and tensin homolog (PTEN). Furthermore, the present study revealed that IL-6 inhibited miR-106a expression by activating STAT3. Tocilizumab, a humanized anti-human IL-6R antibody, that competitively inhibits IL-6/IL-6R signaling, did not inhibit the proliferation and invasion of SKOV3 cells. In conclusion, our studies revealed that miR-106a was significantly increased in the ovarian cancer tissues and cell lines. Downregulation of the expression of miR-106a inhibited cell growth and metastasis of ovarian cancer cells. Together, the present study suggests that miR-106a acts as an oncogene in ovarian cancers.

show abstract

“…by cells from the microenvironment (especially activated immune cells and stromal cells), as well as the increased expression of STAT-3, NF-kB, iNOS and COX-2 in tumor and tumor-surrounding cells, has been linked to poor prognosis, disease stage progression, residual disease status and the presence of ascites [83,85,86]. Among these molecules, IL-6 seems to play a key role in determining platinum-resistance.…”

Section: Parp Inhibitorsmentioning

confidence: 99%

Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

Staropoli¹,

Botta²,

Ciliberto³

et al. 2013

JCT

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is the sixth most common malignancy in women. Ovarian tumors consist of several clinical and pathological entities that share an anatomic site. The gold standard treatment, both in front-line and in adjuvant setting, is represented by carboplatin/paclitaxel combination. Conversely, the second-line treatment is not well defined. The response to platinum is the major prognostic factor for survival. In this review we discuss the current views on platinum-refractory/resistant patient treatment only, which includes patients progressing or relapsing within 6 months from the last platinum-based course. Concerning this subgroup, the activity of several conventional drugs was confirmed in different trials without a significant impact in terms of overall survival. In the last years particular emphasis was given to targeted anti-angiogenetic therapy which produced a survival improvement with an acceptable toxicity profile. New "ad hoc" approaches, with a major attention to outcome-predictive factors, are eagerly awaited.

show abstract

Inflammation and ovarian cancer

Cited by 250 publications

References 82 publications

The emerging role of CXC chemokines in epithelial ovarian cancer

The emerging role of CXC chemokines in epithelial ovarian cancer

MicroRNA-106a regulates phosphatase and tensin homologue expression and promotes the proliferation and invasion of ovarian cancer cells

Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

Contact Info

Product

Resources

About